kabutan

ONO PHARMA, 34% Increase in Net Income for The Current Fiscal Year

Thu May 8, 2025 12:00 pm JST Earnings

4528 ONO PHARMACEUTICAL CO., LTD. 【IFRS】

Earnings Report

ONO PHARMACEUTICAL CO., LTD. <4528> [TSE Prime] announced its financial results (based on IFRS) at noon (12:00) on May 8th. The consolidated net income for the fiscal year ending March 2025 dropped 60.9% from the previous period to 50 billion yen. For the fiscal year ending March 2026, the consolidated net income is expected to recover to 33.9% to 67 billion yen.

In the most recent three-month period, from January to March (4Q), the consolidated net income/loss turned to a loss of 6.54 billion yen (compared to a profit of 17.4 billion yen in the same period last year). The operating profit/loss margin drastically worsened from 13.6% in the same period last year to -9.8%.

Kabutan News

Actual Results

Historical Performance
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2023 447,187 141,963 143,532 112,723 230.9 70 May 10, 2023 IFRS
Mar, 2024 502,672 159,935 163,734 127,977 266.6 80 May 9, 2024 IFRS
Mar, 2025 486,871 59,747 59,328 50,047 106.6 80 May 8, 2025 IFRS
YoY -3.1% -62.6% -63.8% -60.9% -60.0%

Full Year Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2025 Guidance 487,000 60,000 60,000 50,000 106.5 80 Apr 28, 2025 IFRS
Mar, 2025 Results 486,871 59,747 59,328 50,047 106.6 80 May 8, 2025 IFRS
Revision Rate 0.0% -0.4% -1.1% +0.1% +0.1%

Current Period Guidance

H1 Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2024 240,339 48,788 47,544 37,435 79.7 40 Oct 31, 2024 IFRS
Apr - Sep, 2025 Guidance ー ー ー ー － 40 May 8, 2025 IFRS
YoY － － － － －

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 502,672 159,935 163,734 127,977 266.6 80 May 9, 2024 IFRS
Mar, 2025 486,871 59,747 59,328 50,047 106.6 80 May 8, 2025 IFRS
Mar, 2026 Guidance 490,000 85,000 85,000 67,000 142.6 80 May 8, 2025 IFRS
YoY +0.6% +42.3% +43.3% +33.9% +33.8%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jan - Mar, 2024 112,769 15,309 16,442 17,433 36.3 13.6 May 9, 2024 IFRS
Apr - Jun, 2024 117,675 30,690 33,310 24,794 52.8 26.1 Jul 31, 2024 IFRS
Jul - Sep, 2024 122,664 18,098 14,234 12,641 26.9 14.8 Oct 31, 2024 IFRS
Oct - Dec, 2024 134,223 21,966 24,493 19,157 40.8 16.4 Feb 3, 2025 IFRS
Jan - Mar, 2025 112,309 -11,007 -12,709 -6,545 -13.9 -9.8 May 8, 2025 IFRS
YoY -0.4% － － － －

Related Articles